Clovis Oncology is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and other international markets. The company's product candidates include Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP) that is being tested in multiple clinical trials to treat ovarian and other cancers, and Lucitanib, an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs) that is being tested in multiple clinical trials to treat solid tumors. Clovis Oncology was founded in 2009 and is headquartered in Boulder, Colorado.